(1 - 17 von 20
)
Brensocatib (Formerly INS1007) to be Studied in Patients with Severe...
edition.cnn.com
View market sector performance relative to the S&P 500 Index and trended stock performance over time.
Surviving a stroke means knowing the symptoms — and acting quickly |...
nationalpost.com
Martina Flammer. “Some of them you can influence: you can stop smoking, you can make healthy lifestyle choices. Some of them, you cannot ...
Insmed appoints Martina Flammer as Chief Medical Officer, provides...
www.oindpnews.com
Insmed has announced the appointment of Martina Flammer as Chief Medical Officer, effective mid-December Flammer was most ...
Boehringer Ingelheim to provide treatment option for Leukemia...
patientdaily.com
... investigational medicines targeting AML together," Dr. Martina Flammer, vice president of clinical development at Boehringer Ingelheim, said.
Drug trial aims to treat severe outcome of COVID Life Sciences...
www.lifesciencesscotland.com
Martina Flammer, M.D., Chief Medical Officer of Insmed, said, “The global COVID-19 pandemic has generated an extraordinary response from ...
Drug trial aims to treat severe outcome of COVID-19 | Dundee and...
www.dundeeandanguschamber.co.uk
Drug trial aims to treat severe outcome of COVID Dundee and Angus Chamber of Commerce - Researchers from the University’s School of Medicine are...
FAA bans anti-smoking drug - Los Angeles Times
www.latimes.com
Chantix is prohibited for pilots and air traffic controllers in response to a new report on risky side effects.
INSMED: Receives FDA Breakthrough Therapy Designation for Brensocatib...
fdahealthnews.com
Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020
Insmed's drug gets US FDA breakthrough-therapy tag for respiratory...
www.spglobal.com
... the drug helped reduce the severity of symptoms in certain patients with the disease — said Insmed's Chief Medical Officer Martina Flammer.
Interim sub-group analysis shows the reversal agent idarucizumab*...
www.newswire.ca
... most patients, allowing urgent surgery to be initiated rapidly," said Dr. Martina Flammer, Vice President, Medical and Drug Regulatory Affairs, ...
Loop | The Marketing Disruption Summit USA
www.frontiersin.org
Martina Flammer, SVP, Customer Value, Boehringer Ingelheim • Judith Lyster, Digital/IT Leader Canada, Eli Lilly and Co. • Matt Smith, Global ...
| NDAQ:INSM | Press Release | Insmed Inc.
stockhouse.com
New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis
Canadian Life Sciences Database
www.canadianlifesciences.com
Search the Canadian Life Sciences Database and identify potential partners in the Canadian Biotech, Pharma and Medtech industry
Non-CF Bronchiectasis Drug Brensocatib Gets FDA Breakthrough Status
bronchiectasisnewstoday.com
The U.S. Food and Drug Administration has granted breakthrough therapy status to Insmed’s brensocatib to treat non-cystic fibrosis bronchiectasis in …s.
Ofev Named an Orphan Drug to Treat Scleroderma in Europe and US
sclerodermanews.com
Read about Boehringer's Ofev being named an Orphan Drug in Europe and US as a possible scleroderma treatment, and a large Phase 3 study recruiting patients.
University of Dundee: World-first clinical trial raises hopes of new...
www.marketscreener.com
A drug which reduces the risk of people living with a chronic lung disease from needing antibiotics or emergency hospital treatment could soon be a reality,...
sortiert nach Relevanz / Datum